Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
<p>Abstract</p> <p>Background</p> <p>Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the prevention of...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-06-01
|
Series: | Malaria Journal |
Subjects: | |
Online Access: | http://www.malariajournal.com/content/11/1/207 |
id |
doaj-a1f81a1825624ad2ae95797ed1fb4355 |
---|---|
record_format |
Article |
spelling |
doaj-a1f81a1825624ad2ae95797ed1fb43552020-11-24T22:06:24ZengBMCMalaria Journal1475-28752012-06-0111120710.1186/1475-2875-11-207Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatmentShaukat Ayesha MGilliams Elizabeth AKenefic Leo JLaurens Matthew BDzinjalamala Fraction KNyirenda Osward MThesing Phillip CJacob Christopher GMolyneux Malcolm ETaylor Terrie EPlowe Christopher VLaufer Miriam K<p>Abstract</p> <p>Background</p> <p>Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the prevention of subsequent episodes of malaria infection is not reported as a study outcome. However, in moderate and high transmission settings, new infections are common and the ability of a short-acting medication to cure an initial infection may be outweighed by its inability to prevent the next imminent infection. The clinical benefit of preventing new infections has never been compared to that of curing the initial infection.</p> <p>Methods</p> <p>Children enrolled in a sulphadoxine-pyrimethamine efficacy study in Blantyre, Malawi from 1998–2004 were prospectively evaluated. Six neutral microsatellites were used to classify new and recrudescent infections in children aged less than 10 years with recurrent malaria infections. Children from the study who did not experience recurrent parasitaemia comprised the baseline group. The odds of fever and anaemia, the rate of haemoglobin recovery and time to recurrence were compared among the groups.</p> <p>Results</p> <p>Fever and anemia were more common among children with parasitaemia compared to those who remained infection-free throughout the study period. When comparing recrudescent vs. new infections, the incidence of fever was not statistically different. However, children with recrudescent infections had a less robust haematological recovery and also experienced recurrence sooner than those whose infection was classified as new.</p> <p>Conclusions</p> <p>The results of this study confirm the paramount importance of providing curative treatment for all malaria infections. Although new and recrudescent infections caused febrile illnesses at a similar rate, recurrence due to recrudescent infection did have a worsened haemological outcome than recurrence due to new infections. Local decision-makers should take into account the results of genotyping to distinguish new from recrudescent infections when determining treatment policy on a population level. It is appropriate to weigh recrudescent malaria more heavily than new infection in assessing treatment efficacy.</p> http://www.malariajournal.com/content/11/1/207MalariaSulphadoxine-pyrimethamineDrug efficacyGenotypingRecrudescent infectionsNew infectionsMalawiAnaemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shaukat Ayesha M Gilliams Elizabeth A Kenefic Leo J Laurens Matthew B Dzinjalamala Fraction K Nyirenda Osward M Thesing Phillip C Jacob Christopher G Molyneux Malcolm E Taylor Terrie E Plowe Christopher V Laufer Miriam K |
spellingShingle |
Shaukat Ayesha M Gilliams Elizabeth A Kenefic Leo J Laurens Matthew B Dzinjalamala Fraction K Nyirenda Osward M Thesing Phillip C Jacob Christopher G Molyneux Malcolm E Taylor Terrie E Plowe Christopher V Laufer Miriam K Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment Malaria Journal Malaria Sulphadoxine-pyrimethamine Drug efficacy Genotyping Recrudescent infections New infections Malawi Anaemia |
author_facet |
Shaukat Ayesha M Gilliams Elizabeth A Kenefic Leo J Laurens Matthew B Dzinjalamala Fraction K Nyirenda Osward M Thesing Phillip C Jacob Christopher G Molyneux Malcolm E Taylor Terrie E Plowe Christopher V Laufer Miriam K |
author_sort |
Shaukat Ayesha M |
title |
Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment |
title_short |
Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment |
title_full |
Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment |
title_fullStr |
Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment |
title_full_unstemmed |
Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment |
title_sort |
clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment |
publisher |
BMC |
series |
Malaria Journal |
issn |
1475-2875 |
publishDate |
2012-06-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the prevention of subsequent episodes of malaria infection is not reported as a study outcome. However, in moderate and high transmission settings, new infections are common and the ability of a short-acting medication to cure an initial infection may be outweighed by its inability to prevent the next imminent infection. The clinical benefit of preventing new infections has never been compared to that of curing the initial infection.</p> <p>Methods</p> <p>Children enrolled in a sulphadoxine-pyrimethamine efficacy study in Blantyre, Malawi from 1998–2004 were prospectively evaluated. Six neutral microsatellites were used to classify new and recrudescent infections in children aged less than 10 years with recurrent malaria infections. Children from the study who did not experience recurrent parasitaemia comprised the baseline group. The odds of fever and anaemia, the rate of haemoglobin recovery and time to recurrence were compared among the groups.</p> <p>Results</p> <p>Fever and anemia were more common among children with parasitaemia compared to those who remained infection-free throughout the study period. When comparing recrudescent vs. new infections, the incidence of fever was not statistically different. However, children with recrudescent infections had a less robust haematological recovery and also experienced recurrence sooner than those whose infection was classified as new.</p> <p>Conclusions</p> <p>The results of this study confirm the paramount importance of providing curative treatment for all malaria infections. Although new and recrudescent infections caused febrile illnesses at a similar rate, recurrence due to recrudescent infection did have a worsened haemological outcome than recurrence due to new infections. Local decision-makers should take into account the results of genotyping to distinguish new from recrudescent infections when determining treatment policy on a population level. It is appropriate to weigh recrudescent malaria more heavily than new infection in assessing treatment efficacy.</p> |
topic |
Malaria Sulphadoxine-pyrimethamine Drug efficacy Genotyping Recrudescent infections New infections Malawi Anaemia |
url |
http://www.malariajournal.com/content/11/1/207 |
work_keys_str_mv |
AT shaukatayesham clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT gilliamselizabetha clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT keneficleoj clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT laurensmatthewb clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT dzinjalamalafractionk clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT nyirendaoswardm clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT thesingphillipc clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT jacobchristopherg clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT molyneuxmalcolme clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT taylorterriee clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT plowechristopherv clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment AT laufermiriamk clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment |
_version_ |
1725824015150350336 |